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MaBACKGROUND Microvascular dysfunction plays an important role in the pathogenesis of heart failure with preserved
ejection fraction (HFpEF). However, no mechanistic link between systemic microvasculature and congestion, a central
feature of the syndrome, has yet been investigated.
OBJECTIVES This study aimed to investigate capillary–interstitium fluid exchange in HFpEF, including lymphatic
drainage and the potential osmotic forces exerted by any hypertonic tissue Naþ excess.
METHODS Patients with HFpEF and healthy control subjects of similar age and sex distributions (n ¼ 16 per group)
underwent: 1) a skin biopsy for vascular immunohistochemistry, gene expression, and chemical (water, Naþ, and Kþ)
analyses; and 2) venous occlusion plethysmography to assess peripheral microvascular filtration coefficient (measuring
capillary fluid extravasation) and isovolumetric pressure (above which lymphatic drainage cannot compensate for fluid
extravasation).
RESULTS Skin biopsies in patients with HFpEF showed rarefaction of small blood and lymphatic vessels (p ¼ 0.003 and
p ¼ 0.012, respectively); residual skin lymphatics showed a larger diameter (p ¼ 0.007) and lower expression of
lymphatic differentiation and function markers (LYVE-1 [lymphatic vessel endothelial hyaluronan receptor 1]: p < 0.05;
PROX-1 [prospero homeobox protein 1]: p < 0.001) compared with control subjects. In patients with HFpEF,
microvascular filtration coefficient was lower (calf: 3.30 [interquartile range (IQR): 2.33 to 3.88] l  100 ml of tissue–1 
min–1  mm Hg–1 vs. 4.66 [IQR: 3.70 to 6.15] ml  100 ml of tissue–1  min–1  mm Hg–1; p < 0.01; forearm: 5.16 [IQR: 3.86
to 5.43] l  100 ml of tissue–1  min–1  mm Hg–1 vs. 5.66 [IQR: 4.69 to 8.38] ml  100 ml of tissue–1  min–1  mm Hg–1;
p > 0.05), in keeping with blood vascular rarefaction and the lack of any observed hypertonic skin Naþ excess, but the
lymphatic drainage was impaired (isovolumetric pressure in patients with HFpEF vs. control subjects: calf 16  4 mm Hg vs.
22  4 mm Hg; p < 0.005; forearm 17  4 mm Hg vs. 25  5 mm Hg; p < 0.001).
CONCLUSIONS Peripheral lymphatic vessels in patients with HFpEF exhibit structural and molecular alterations and
cannot effectively compensate for fluid extravasation and interstitial accumulation by commensurate drainage. Reduced
lymphatic reserve may represent a novel therapeutic target. (J Am Coll Cardiol 2020;76:2817–29)
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ABBR EV I A T I ON S
AND ACRONYMS
BNP = B-type natriuretic
peptide
BP = blood pressure
CVP = central venous pressure
DD = deep dermis
ESD = epidermis and superficial
dermis
HC = healthy control
HF = heart failure
HFpEF = heart failure with
preserved ejection fraction
Kf = microvascular filtration
coefficient
Pi = isovolumetric pressure
PV = venous pressure
VEGF = vascular endothelial
growth factor
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2818H eart failure (HF) is a leading causeof morbidity and mortality (1). Cur-rent trends of increased HF hospi-
talizations are mostly driven by HF with
preserved ejection fraction (HFpEF), carrying
a 1-year prognosis almost as poor as in pa-
tients with HF with reduced ejection fraction
(2–4).
HFpEF is a clinical syndrome closely
associated with multiple cardiovascular
comorbidities and risk factors, such as hy-
pertension, obesity, coronary artery disease,
diabetes mellitus, atrial fibrillation, and
chronic kidney disease (5). The notion that
these comorbidities not only are associated
with HFpEF, but also may be directly
involved in its pathogenesis via comorbidity-
associated inflammation and coronary
microvascular dysfunction (6) has gained
support from a large body of postmortem,noninvasive, and invasive evidence (7–9). In addition
to the coronary vascular bed, peripheral vessels also
appear dysfunctional (8). In particular, impaired
systemic vasodilator reserve and low skeletal muscle
capillary density, as well as low peripheral O2
extraction paralleling microvascular rarefaction, were
reported as determinants of exercise intolerance in
patients with HFpEF (4,10–12). Such findings chal-
lenged the paradigm of a purely cardiac disorder in
favor of a more systemic phenomenon (13). However,
whether and how a dysfunctional microcirculation
could directly impact congestion, “the core of the HF
syndrome” (5), has not yet been investigated.
In recent years, understanding of body fluid ho-
meostasis has evolved through reappraisal of tissue
sodium (Naþ) accumulation. This phenomenon was
proposed to be water-independent (14) and to induce
a hypertonicity-driven lymphatic network expansion
in order to facilitate local Naþ drainage (15). Notably,
tissue Naþ excess was found in most of the conditions
and risk factors associated with the clinical HFpEF
syndrome (i.e., older age, hypertension, diabetes, and
chronic kidney disease) (16–18), but its hypertonic
nature and functional relevance to fluid homeostasis
in HFpEF lacks demonstration.SEE PAGE 2830Therefore, the HAPPIFY (Heart fAilure with Pre-
served ejection fraction: Plethysmography for Inter-
stitial Function and skin biopsY) study was designed
to investigate capillary–interstitium fluid exchange
and to test the hypothesis that an osmotic effect
secondary to high interstitial Naþ levels could impactmicrovessels and result in excess fluid extravasation
and edema in patients with HFpEF.
METHODS
STUDY PROTOCOL AND SUBJECTS. Subjects with
stable HFpEF, identified from outpatient HF clinics in
Glasgow, United Kingdom (n ¼ 16), and volunteers of
similar age and sex distributions, with no history of
cardiovascular or renal disease, hypertension, or
diabetes (healthy control [HC] subjects; n ¼ 16), were
recruited between August 2017 and December 2018.
HFpEF diagnosis was per the 2016 European Society
of Cardiology guideline definition: 1) signs or symp-
toms of HF; 2) elevated B-type natriuretic peptide
(BNP) >35 pg/ml; 3) ejection fraction $50%; and 4)
evidence of structural heart disease (left atrial
enlargement or left ventricular hypertrophy) or dia-
stolic dysfunction (19). Exclusion criteria were a his-
tory of recent (<3 months) cerebrovascular event,
myocardial infarction, or coronary revascularization;
significant valve disease; unstable coronary artery
disease; hypertrophic or infiltrative cardiomyopathy
or constrictive pericarditis; chronic kidney disease
stage >3; idiopathic edema or capillary leak syn-
drome, myxedema, or lymphatic obstruction; sys-
temic inflammation at the time of study visit; active
malignancy; any major hypercoagulable state or his-
tory of venous thrombosis or embolism on no ongoing
anticoagulation; and incapacity.
Eligibility and main visits were conducted in the
morning, in a temperature-controlled room. Subjects
did not consume caffeine, alcohol, or food; did not
smoke; and avoided vasoactive or diuretic medica-
tions for >4 h prior to assessments. The study pro-
cedures included history and physical examination;
full blood count, BNP, hemoglobin A1c, and renal,
liver, and thyroid function; urinary albumin-to
creatinine ratio (morning spot sample); simulta-
neous bilateral brachial and calf blood pressure (BP)
measurement; pulsed wave velocity; echocardiogra-
phy; flow-mediated dilatation; venous occlusion
strain gauge plethysmography; and a gluteal skin
punch biopsy. Participants who were not on antico-
agulants and who had no history of severe obstructive
iliac artery disease were offered to participate in an
optional substudy, involving a larger surgical excision
of skin and subcutaneous fat tissue around the site of
the punch biopsy, for dissection of resistance arteries
and molecular biology. This study conforms to the
Declaration of Helsinki and the protocol was
approved by the West of Scotland Research Ethics
Committee 3 (ref. 17/WS/0091) and Greater Glasgow
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GN17CA152).
TISSUE SAMPLES. All participants (except for 1
patient, owing to ineffective anesthesia) underwent a
4-mm skin punch biopsy on a gluteal external upper
quadrant, after topical numbing with Naþ-free lido-
caine cream (LMX4, Ferndale Pharma Group, Fern-
dale, Michigan) as described (20). One-half of the skin
sample was fixed in paraformaldehyde 2% for histol-
ogy, and the other one-half was immediately frozen
and stored at –80C until chemical analysis.
A skin portion of the larger biopsies obtained from
participants eligible and consenting also to the sub-
study was immediately frozen for molecular biology
(7 patients with HFpEF and 10 HC subjects); the
remaining tissue was used to dissect small resistance
arteries for ex vivo functional testing of endothelium-
dependent and endothelium-independent relaxation
by wire myography.
SKIN HISTOCHEMICAL ANALYSIS. As reported (20),
frozen skin samples were cut into a superficial layer
(including the epidermis and superficial dermis [ESD])
and deep dermis (DD) layer in a cold room, to prevent
evaporation. Tissue water content was estimated as
wet weight  dry weight (DW), determined after
desiccation at 65C for >40 h to stable weight. Tissue
Naþ and Kþ were measured in the HNO3-digested dry
samples by flame photometry (410C, Sherwood Sci-
entific, Cambridge, United Kingdom) and expressed as
absolute content (mmol/g DW) or concentration
(mmol/l, after normalization by tissue water).
SKIN MICROVASCULAR IMAGING. Paraffin-embedded
skin sections (5-mm thick) including both epidermis
and dermis were stained with anti-human LYVE-1
(lymphatic vessel endothelial hyaluronan receptor 1)
antibody (R&D Systems, Minneapolis, Minnesota;
3 mg/ml, overnight, 4C; matched isotype goat
immunoglobulin G as negative control), after over-
night low-temperature antigen retrieval (Unitrieve;
Innovex Biosciences, Richmond, California) and
nonspecific signal blocking. Alexa fluor 488–conju-
gated secondary antibody (2 mg/ml; Invitrogen,
Carlsbad, California) and Ulex europaeus agglutinin I
lectin (10 mg/ml; Vector Laboratories, Burlingame,
California) were used to stain LYVE-1þ lymphatic
vessels and blood endothelial cells, respectively.
Tiled images of the entire epidermal line and the
subpapillary dermis were acquired at 20 magnifica-
tion. Blinded automated image analysis for micro-
vessels quantification in the 600-mm-thick dermal
area starting from the epidermis–dermis junction and
spanning the entire length of the biopsy was per-
formed with ImageJ version 1.52q (National Institutesof Health, Bethesda, Maryland), by pre-defined ho-
mogeneous thresholding criteria and the “analyze
particles” function (Supplemental Figure 1).
SKIN GENE EXPRESSION ANALYSIS. RNA was
extracted from gluteal surgical biopsies. After pre-
amplification (TaqMan PreAmp technology, Applied
Biosystems, Foster City, California) of target com-
plementary DNA, a Custom TaqMan Array Card
(Thermo Fisher Scientific, Waltham, Massachusetts)
was used to perform quantitative gene expression of
markers or growth and transcription factors specific
to blood or lymphatic vessels. Gene expression levels
were compared and presented as DCt values, with b-
actin as housekeeping gene.
PLETHYSMOGRAPHY AND MICROVASCULAR FLUID
DYNAMICS. Strain gauge plethysmography (EC6,
Hokanson, Carmel, Indiana), measuring limb volume
changes as ml/100 ml of tissue, was used to assess
forearm and calf arterial blood flow, peripheral
venous pressure (PV) (as a surrogate for central
venous pressure [CVP]) and net fluid extravasation
toward the interstitium at increasing venous
occluding pressures, as described previously (21–25).
Briefly, strain gauges were positioned on the
nondominant forearm and on the ipsilateral calf and
were maintained at the height of the right atrium.
Inflatable cuffs for venous occlusion were placed
proximal to the strain gauges. PV was determined by
gradually increasing the occlusion pressure, sustained
until any limb volume change was detected. Arterial
blood flow was determined from the rate of change in
limb volume after consecutive cycles of sudden
venous occlusion to 45mmHg (E20Rapid Cuff Inflator,
D.E. Hokanson Inc., Bellevue, Washington), as
described previously (22). Arterial resistance to flow
was calculated as: (mean BP  PV) / blood flow (24).
To assess microvascular filtration parameters, we
used cumulative 8-mm Hg occluding pressure steps,
lasting 3.5 min each and starting at the first multiple
exceeding PV, up to a maximum of 56 mm Hg or less
if diastolic BP was lower. The pressure applied to the
cuff and transmitted to the veins induces their
distension and filling, with a curvilinear initial phase
and a later plateau (Supplemental Figure 2A). How-
ever, above a certain equilibrium pressure up to
which any fluid filtering across the microvascular
interface is being removed at an equivalent rate by
lymphatic drainage, interstitial fluid accumulation
occurs, thus resulting in a linear increase in limb
volume (Supplemental Figure 2B). This pressure
threshold is called isovolumetric pressure (Pi). The
time course (i.e., slope) of this interstitial fluid
accumulation was calculated as the averaged first




(n ¼ 16) p Value
Female 11 (69) 10 (63) 0.710
Age, yrs 68  5 72  6 0.060
BMI, kg/m2 25.1  2.9 33.9  4.4 <0.001
Overweight/obese 8 (50)/1 (6) 4 (25)/12 (75) <0.001
BSA, m2 1.78  0.21 2.00  0.28 0.021
SBP, mm Hg 130  14 146  21 0.017
DBP, mm Hg 73  8 71  14 0.659
HR, beats/min 60  7 65  16 0.256
Left atrial volume index, ml/m2 23.3  6.1 46.8  12.8 <0.001
Left ventricular mass index, g/m2 84.3  17.9 127.8  26.6 <0.001
Left ventricular ejection fraction, % 63.2  3.5 60.8  6.7 0.222
E/e0 8.0  1.6 10.8  2.9 0.001
Comorbidity
Hypertension — 15 (94) <0.001
Coronary artery disease — 3 (20) 0.060
Atrial fibrillation — 11 (69) <0.001
Diabetes mellitus — 7 (44) 0.003
Chronic kidney disease — 7 (44) 0.003
Smoking (current/prior) 0 (0)/2 (13) 3 (19)/7 (44) 0.011
Medication
ACE inhibitor/ARB — 14 (88) <0.001
BB — 14 (88) <0.001
CCB — 3 (19) 0.069
Diuretic (loop/thiazide) — 15 (94)/1 (6) <0.001
MRA — 1 (6) 0.310
Long-acting nitrates — 2 (13) 0.144
Statin — 8 (50) 0.001
Digoxin — 5 (31) 0.015
Aspirin — 4 (25) 0.033
Anticoagulation — 7 (44) 0.003
Naþ 140 (139–142) 140 (136–142) 0.361
Kþ 4.5 (4.2–4.7) 4.2 (4.0–4.7) 0.224
Urea, mmol/l 5.5 (4.7–6.0) 6.4 (5.9–9.8) 0.007
Creatinine, mmol/l 71 (59–84) 79 (67–90) 0.138
eGFR (CKD-EPI), ml/min/1.73 m2 81.7  11.0 70.9  17.0 0.042
Urinary ACR, mg/gCr 4.8 (3.2–6.1) 33.9 (10.7–87.4) 0.001
Hemoglobin, g/l 145  8.8 133  17 0.022
Hematocrit, % 44.1  2.5 40.5  4.7 0.013
Albumin, g/l 39.3  3.1 37.8  2.7 0.155
BNP, pg/ml 24 (16–32) 170 (93–320) <0.001
Values are n (%), mean  SD, or median (interquartile range). Chronic kidney disease was defined as
eGFR <60 ml/min/1.73 m2.
ACE ¼ angiotensin-converting enzyme; ACR ¼ albumin to creatinine ratio; ARB ¼ angiotensin receptor blocker;
BB ¼ beta-blocker; BMI ¼ body mass index; BNP ¼ B-type natriuretic peptide; BSA ¼ body surface area (Mos-
teller); CCB ¼ calcium-channel blocker; CKD-EPI ¼ Chronic Kidney Disease Epidemiology Collaboration;
DBP ¼ diastolic blood pressure; E/e0 ¼ average of septal and lateral velocity ratio; eGFR ¼ estimated glomerular
filtration rate; HC ¼ healthy control; HFpEF ¼ heart failure with preserved ejection fraction; HR ¼ heart rate;
MRA ¼ mineralocorticoid receptor antagonist; SBP ¼ systolic blood pressure.
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capillary hydrostatic pressure (¼ pressure applied to
the cuff) step, in portions devoid of motion artifacts
and excluding the venous filling phase (LabChart,
ADInstruments, Sydney, Australia); these slopes are
proportional to hydrostatic pressure by a
coefficient called microvascular filtration coefficient(Kf) (ml  100 ml of tissue–1  min–1  mm Hg–1)
(Supplemental Figure 2C) (21). The filtration coeffi-
cient, as well as the pressure when extravasation
and lymphatic drainage balance and the net increase
in tissue volume is null (i.e., the intercept of the
linear association with the x-axis; Pi), were deter-
mined for each limb and participant, blindly to
group allocation, by least-squares regression (Prism,
version 8; GraphPad Software, San Diego, California).
Limbs with <3 points free of motion artifacts for
regression fitting (21,26) or with pre-defined limb-
specific exclusion criteria were excluded from
analysis.
STATISTICAL ANALYSIS. Recruitment was stopped
after 16 of 20 initially estimated subjects per group,
when interim analysis showed futility in relation to
the primary hypothesis of a higher Kf in patients with
HFpEF compared with HC subjects. All statistical an-
alyses were performed using Prism and SPSS version
25 (IBM Corporation, Armonk, New York). Categorical
variables were compared by chi-square test. Contin-
uous variables were tested for normality of distribu-
tion by graphical plotting and Kolmogorov-Smirnov
test. Parametric or nonparametric unpaired unad-
justed tests were used for comparison of primary
(microvascular) and secondary endpoints between
groups, accordingly. Least-squares fit was used for
both nonlinear regression and linear regression. The a
level was set at 0.05, and all statistical tests were
2-tailed.
An extended description of the study methods is
available in the Supplemental Appendix.
RESULTS
SUBJECT CHARACTERISTICS AND VASCULAR
FUNCTION. Clinical characteristics of the 2 study
groups are provided in Table 1. Patients with HFpEF
and HC subjects were similar for age and sex distri-
butions. Patients with HFpEF showed typical char-
acteristics, with high prevalence of hypertension,
obesity, paroxysmal or permanent atrial fibrillation,
left ventricular hypertrophy and signs of atrial
remodeling or diastolic dysfunction (Supplemental
Table 1), diabetes, and chronic kidney disease.
Compared with HC subjects, they had higher BNP,
albuminuria, and plasma urea, and lower eGFR and
hematocrit, but similar plasma albumin.
Classical assessment of peripheral vascular func-
tion also revealed higher carotid-femoral pulsed wave
velocity, as a measure of stiffness of large arteries,
and lower brachial flow-mediated dilatation, which
was accompanied by lower post-ischemic reactive
hyperemia (Supplemental Table 2, Supplemental
FIGURE 1 Chemical Analysis of the Skin






































































































































































(A, B) Water content (% of wet weight [WW]), Naþ content (mmol/g of tissue dry weight [DW]), Naþ concentration, and [Naþ þ Kþ] concentration (mmol/l of tissue
water) in the outer (epidermis and superficial dermis [ESD]) and the inner (deep dermis [DD]) layers of the skin biopsies. (C) Representative skin sections from a healthy
control (HC) subject and a patient with heart failure with preserved ejection fraction (HFpEF) (picrosirius red staining). The dashed line identifies the cutting plane for
separation of ESD and DD in all study samples, scale bars are at the bottom, and black-circled areas represent dermal fat, quantified in the sections as % of biopsy area
and were more abundant in patients with HFpEF than in HC subjects. (B) Excess dermal fat parallels the reduced volume of distribution of water and Naþ and,
accordingly, their reduced content observed in the DD of patients with HFpEF. All data in panels A–C are presented as mean  SD; * p < 0.05, **p < 0.01.
(D) Association between Na and water content, including both ESD and DD values; the slope of the regression line was the same between study groups.
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Skin microvascular anatomy assessed as density (number of vessels/mm2 tissue), average cross-sectional area of the vessels (average size; mm2), and total stainþ area
(expressed as percentage of the dermal area) of the vessels identified in the section. (A) Blood vessels (BVs) showed a reduction in number and total areaþ; (B)
lymphatic vessels (LVs) were reduced in number but, on average, were larger in size in patients with HFpEF compared with HC subjects. (C) Representative sections,
showing blood vessels (lectinþ [red]) and lymphatic vessels (LYVE-1 [lymphatic vessel endothelial hyaluronan receptor 1] [green]); arrowheads indicated small
terminal lymphatic vessels, reduced in HFpEF compared with HC subjects, and larger vessels appeared unaffected. Scale bar at bottom right ¼ 200 mm. (D) Gene
expressions, presented as DCt (the higher the value, the lower the gene expression; b-actin as housekeeping gene); colored bars on top to indicate blood (red),
lymphatic (green), or mixed vascular specificity; x ¼ automatically detected outlier (ROUT ¼ 1%) (GraphPad Prism). All data are presented as mean  SD; *p < 0.05,
**p < 0.01, ***p < 0.001. PROX-1 ¼ prospero homeobox protein 1; VEGF ¼ vascular endothelial growth factor; VEGFR ¼ vascular endothelial growth factor receptor;
other abbreviations as in Figure 1.
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TABLE 2 Microvascular Dynamics
HC Subjects (n ¼ 16) Patients With HFpEF (n ¼ 16) p Value
Forearm
Mean arterial pressure, mm Hg 92  7 94  12 0.529
Blood flow, ml  100 ml of tissue–1  min–1 1.9  0.8 1.9  0.9 0.992
Arterial peripheral resistance, mm Hg/ml  100 ml tissue–1  min–1 50.1  14.5 56.3  29.5 0.459
Venous pressure, mm Hg 5 (4–6) 8 (7–10) <0.001
Filtration coefficient (Kf), ml  100 ml of tissue–1  min–1  mm Hg–1 5.66 (4.69–8.38) 5.16 (3.86–5.43) 0.234
Isovolumetric pressure, mm Hg 25  5 17  4 <0.001
Calf
Mean arterial pressure, mm Hg 94  8 96  14 0.555
Blood flow, ml  100 ml of tissue–1  min–1 3.3  1.6 3.6  1.4 0.573
Arterial peripheral resistance, mm Hg/ml  100 ml tissue–1  min–1 33.1  15.4 29.3  11.8 0.459
Venous pressure, mm Hg 5 (4–5) 7 (7–9) <0.001
Filtration coefficient (Kf) ml  100 ml of tissue–1  min–1  mm Hg–1 4.66 (3.70–6.15) 3.30 (2.33–3.88) 0.008
Isovolumetric pressure, mm Hg 22  4 16  4 0.003
Values are mean  SD or median (interquartile range).
Abbreviations as in Table 1.
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2823Figure 3). Consistently, ex vivo vasodilation of sub-
cutaneous resistance arteries was reduced in patients
with HFpEF compared with HC subjects
(Supplemental Figure 4).
SKIN SALT. The chemical analysis of gluteal skin bi-
opsies revealed that water content (% wet weight
[mg/mg dry weight] [not shown]), Naþ concentration
(mmol/l of water), and total Naþ content (mmol/g
DW) in the ESD were similar between patients with
HFpEF and HC subjects (Figure 1A). In the DD, water
and Naþ content were lower in patients with HFpEF
than in HC subjects (Figure 1B), in keeping with the
distribution of body mass index and dermal fat
(Figure 1C, Supplemental Figure 5), which limits the
volume of distribution of both water and electrolytes
in the tissue while leaving their relative representa-
tion overall unaffected. DD Naþ and (Naþ þ Kþ) con-
centrations (i.e., upon content normalization for
water) were similar between groups, as in ESD. Naþ þ
Kþ concentration consistently fell within a physio-
logical range (140 to 155 mmol/l) (20) in both layers.
Likewise, the slope of the regression line for skin
water and Naþ content did not differ by group
(p ¼ 0.810) (Figure 1D) or tissue layer (ESD vs. DD,
p ¼ 0.922) (not shown). In summary, we did not
detect any hypertonic, water-independent accumu-
lation of Naþ in the skin of patients with HFpEF.
RAREFACTION OF SKIN BLOOD AND LYMPHATIC
MICROVESSELS AND DIFFERENTIAL GENE EXPRESSION.
Blood microvesse ls . Patients with HFpEF had
dermal rarefaction of blood microvessels compared
with HC subjects (p ¼ 0.003) (Figures 2A and 2C), in-
dependent of age (Spearman correlation with numberof vessels: r ¼ –0.141, p ¼ 0.449). No significant dif-
ference was observed in the size of skin vessels or in
the gene expression of vascular endothelial growth
factor A (VEGF-A) and VEGF-B and their blood-vessel
specific receptors (VEGF receptor 1 [VEGFR1] and
VEGFR2); the expression of vascular endothelial
cadherin, present in both blood and lymphatic ves-
sels, was not different either (Figure 2D).
Lymphat ic microvesse ls . Lymphatic vessels were
similarly reduced in number (p ¼ 0.012) but were
larger (p ¼ 0.007) in patients with HFpEF compared
with HC subjects (Figures 2B and 2C). Neither number
nor average vascular size showed significant associ-
ations with age (r ¼ –0.009, p ¼ 0.963; and r ¼ 0.307,
p ¼ 0.099, respectively). In patients with HFpEF, skin
PROX-1 (prospero homeobox protein 1, a LEC-specific
transcription factor driving development and dy-
namic maintenance of lymphatic vessels and valves)
(27,28) and LYVE-1 (a marker of lymphatic endothelial
cells expressed since the most initial vessels), but not
podoplanin (a glycoprotein generally expressed in the
endothelium of lymphatic vessels above a certain
diameter) (29), were reduced compared with HC
subjects. VEGF-C showed a similar trend (p ¼ 0.06),
but the expression of its lymphatic-specific receptor
VEGFR3 did not differ between groups (Figure 2D).
Overall, both structural and molecular skin lymphatic
alterations were detected in patients with HFpEF.
MICROVASCULAR FLUID DYNAMICS: MICROFILTRATION
AND LYMPHATIC CLEARANCE. Patients with HFpEF had
forearm and calf mean blood pressure, rest limb blood
flow (normalized for milliliters of tissue), and arterial
resistance similar to HC subjects; at variance, their






































































Net accumulation of interstitial fluid at different hydraulic pressures, at which cuffs were inflated to oppose venous drainage in the forearm
(left) and the calf (right). Each regression line corresponds to a participant. The slope of the lines is the microvascular coefficient of filtration
(see Table 2). Red lines (HFpEF) intersect the x-axis at lower pressures compared with blue lines (HC subjects; scale magnification below): the
intersect indicates the threshold above which interstitial fluid accumulation starts to develop (isovolumetric pressure [Pi]). Data presented as
mean  SD; **p < 0.01, ***p < 0.001. Pcuff ¼ pressure applied to the cuff; other abbreviations as in Figure 1.
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of overt decompensation (Table 2).
Because of motion artifacts, 3 forearm (1 patient
with HFpEF, 2 HC subjects) and 4 calf (3 patient with
HFpEF, 1 HC subject) tracings were excluded from the
analysis of microfiltration; 1 additional calf tracing
from a patient with HFpEF was excluded as per
procedure-specific exclusion criteria (overt bilateral
venous insufficiency). The net capillary fluid extrava-
sation toward the interstitium (ml  100 ml of tissue–1
min–1), inducedwithprogressively higher PV by stepped
inflations of proximal cuffs, was not increased in patients
with HFpEF above HC subjects as was initially predicted.
In fact, the slope of the regression line between intersti-
tial fluid accumulation and cuff pressure was lower in
patients with HFpEF compared with HC subjects in the
calf (Kf: 3.30 [IQR: 2.33 to 3.88] ml  100 ml of tissue–1 
min–1 mmHg–1 vs. 4.66 [IQR: 3.70 to 6.15] ml 100ml of
tissue–1  min–1  mm Hg–1; p ¼ 0.010); a similar
nonsignificant trend was observed in the forearm
(5.16 [IQR: 3.86 to 5.43] ml  100 ml of tissue–1  min–1 
mm Hg–1 vs. 5.66 [IQR: 4.69 to 8.38] ml  100 ml of
tissue–1  min–1  mm Hg–1) (Table 2, Figure 3). However,
patients with HFpEF also showed a reduced Pi (calf: 16 
4 mm Hg vs. 22  4 mm Hg; p ¼ 0.003; forearm: 17 4 mm Hg vs. 25  5 mm Hg; p < 0.001): in our in vivo
experimental setting, this reflects the critical pressure up
to which lymphatic drainage can fully compensate for
the continuous extravasation of fluid at even low PV, and
no net interstitial fluid accumulation occurs (i.e., the
intercept of the lines with the x-axis) (Figure 3).
In summary, the clearance of interstitial fluid fails
early to meet demands imposed by the capillary
extravasation induced by hydraulic (venous) pressure
in HFpEF.
DISCUSSION
For the first time in the understanding of HFpEF, our
HAPPIFY study extended the concept of microvas-
cular dysfunction to the lymphatic system. Despite
absence of tissue Naþ hypertonic excess to facilitate
edema, we showed that the lymphatic vessels of pa-
tients with HFpEF exhibit structural and molecular
alterations in the skin and cannot effectively
compensate for fluid extravasation and interstitial
accumulation by commensurate drainage. Along with
direct ex vivo evidence of primary dysfunctional
small subcutaneous resistance arteries and rarefac-
tion of skin blood vessels, as already described in
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2825myocardium (9) and in skeletal muscle (11,13), this
functional and structural vascular impairment further
supports the systemic nature of HFpEF syndrome
(13).
RAREFACTION OF MICROVESSELS. Impaired vaso-
dilatation is an established characteristic of patients
with HFpEF and contributes to exercise disability
(4). In our study, this was confirmed not only by
classical indirect approaches like brachial flow-
mediated dilatation and post-ischemic reactive hy-
peremia, but also by the first ex vivo analysis of
vascular endothelium-dependent (via acetylcholine)
and endothelium-independent (via sodium nitro-
prusside) relaxation of systemic resistance arteries
(Supplemental Figures 3 and 4). In vivo, however,
any hyperemic flow response is critically affected
also by the number of ultimate effectors (i.e., ves-
sels), as demonstrated by experimental disruption
of coronary microvasculature in pigs (30). In pa-
tients with HFpEF, the reduced coronary micro-
vascular density found in autopsy samples (9) is
likely to cause pathological heterogeneity and
mismatch in blood supply and demand (31), thus
impairing myocardial O2 extraction and perfor-
mance. Similarly, exercise capacity in HFpEF is
further reduced by low peripheral O2 extraction and
skeletal muscle capillary density (10–12). Here, on
the one hand, we showed that rarefaction of blood
microvessels in HFpEF occurs also in the skin, by
far the largest human organ and key in the regu-
lation of body hemodynamics. On the other hand,
and at variance with the previously mentioned
largely “arteriocentric” paradigms, our findings
prompt reconsideration of the role of microvascu-
lature as a whole, to include functions other than
vascular resistance homeostasis and structures
other than arteries in HFpEF pathogenesis.
INTERSTITIUM, MICROVASCULATURE, AND CONGESTION
IN HFpEF. Congestion (i.e., edema) is central to HF
syndrome (5), but to the best of our knowledge this
study is the first to investigate the fine capillary–
interstitium fluid homeostasis in HFpEF.
Over the last decade, excess Naþ has been reported
in the skin and skeletal muscle of aged hypertensive
patients (16), diabetic patients (17), and chronic kid-
ney disease patients (18). This phenomenon had
originally been described in rodents as water-
independent (14) and capable of stimulating a lym-
phangiogenic signaling pathway to increase the
drainage of tissue Naþ itself (15). Although a direct
demonstration in HFpEF was missing, all of these are
typical comorbidities of patients with the syndrome,
and we hypothesized that hypertonic Naþaccumulation could drag excess fluid out of vessels
and thereby favor edema. Although the concentration
of Naþ in the skin of patients with HFpEF was high
when contrasted to a previously reported cohort of
young healthy subjects (20) (data recalled in
Supplemental Tables 3 and 4 for reference), it was
accompanied also by higher water content and was
not different from control subjects of similar age
distribution, likely reflecting the lack of overt
decompensation of HF and edema in a nondependent
site in our cohort of patients with stable HFpEF. The
excess Naþ and water content in the skin of our par-
ticipants compared with young healthy subjects is
reminiscent of the age-dependent isotonic Naþ
retention observed also in uncomplicated hyperten-
sive patients, reflecting the expansion of the tissue
extracellular volume (20); as in that cohort, the
identical (Naþ þ Kþ) concentration between study
groups rules out any hypertonic Naþ excess. Accord-
ingly, and contrarily to our initial expectations, the
rate of tissue fluid accumulation induced by
increasing hydraulic pressures (i.e., Kf) was not
higher in patients with HFpEF compared with HC
subjects. In keeping with the dependence of Kf on the
vascular surface available for fluid exchange and with
the rarefaction of blood vessels observed in HFpEF, it
actually was lower. It is possible that blood flow in
HFpEF, similar to HC subjects when normalized by
limb volume, was partially diverted from exchanging
capillaries to functional shunting (31); in other con-
ditions characterized by increase in local blood flow
(e.g., postural tachycardia syndrome), Kf was
elevated (24).
At variance with ex vivo preparations, our in vivo
plethysmographic approach accounted not only for
the capillary fluid extravasation regulated by
Starling-Landis balance, but also for the simultaneous
fluid drainage out of the tissue. In fact, contemporary
direct measurements of the hydraulic and oncotic
interstitial forces revealed that under most condi-
tions there is no sustained reabsorption of interstitial
fluid at the venous end of the capillary beds, that
transvascular flow is generally unidirectional (from
the capillary lumen to the interstitium), and that
drainage, up to 8 l/day, is provided by lymphatics
(32). Under the assumption that the osmotic pressure
of albumin (sP) was similar between study groups
based on similar plasma concentrations, the equilib-
rium hydraulic pressure above which net extravasa-
tion of fluids starts to overfill the interstitium (i.e.,
generate edema) is mostly determined by lymphatic
drainage. Our results showed that this pressure (Pi)
was lower in patients with HFpEF compared with HC
subjects in both arms and legs. A lower Pi and a higher
CENTRAL ILLUSTRATION Microvascular Fluid Dynamics and Reduced Lymphatic Reserve in HFpEF
Rossitto, G. et al. J Am Coll Cardiol. 2020;76(24):2817–29.
In healthy subjects, the fluid filtering out of the capillary bed of the blood vasculature (BV) is evenly balanced by commensurate fluid drainage by lymphatic
vasculature (LV); as a result, the physiological amount of interstitial fluid is homeostatically preserved. In heart failure with preserved ejection fraction (HFpEF), the
net fluid extravasation tends to be lower because of the reduced vascular surface available for fluid exchange (i.e., capillary rarefaction) and the possible diversion of
blood flow toward arteriovenous shunts; however, drainage by the impaired lymphatic system is inadequate to meet demands and facilitates accumulation of
interstitial fluid at lower venous pressures. Both anatomical and functional defects (light green) could explain the reduced lymphatic reserve.
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leaves patients with HFpEF with a much lower range
of pressures that can be compensated for by their
lymphatics. In other words, they appear to have
reduced “lymphatic reserve” (Central Illustration).
THE LYMPHATIC SYSTEM. Lymphatic vessels are
organized into a series of coordinated functional
units, each called lymphangion, separated by intra-
luminal 1-way valves and capable of spontaneous
pumping activity. Their physiology has striking
similarities with heart function, namely a systole-
diastole cycle and a contractility modulated by pre-
and afterload, conferring remarkable plasticity in
response to increased requirements (33). The
complexity of contractile machinery, valvular func-
tion, and electromechanical coordination suggests
that also functional impairment, rather than the soleanatomical severance traditionally implicated in most
secondary lymphatic disorders, could contribute to
disease whenever an imbalance develops between
microvascular filtration and lymphatic drainage. It
has indeed been suggested that all “chronic edema
could be considered as synonymous with lymphe-
dema” (34), intended as relative lymphatic failure or
inadequate reserve. Our functional results support
this contention in HFpEF.
The morphological changes observed in skin lym-
phatics, with rarefaction of terminal capillaries and
larger residual vessels, as well as the reduced gene
expression of factors important for lymphangio-
genesis and valve and vascular integrity maintenance
(27,28), offer only preliminary clues as towhat sustains
the functional defect observed in HFpEF. In particular,
we cannot conclusively identify cause and effect.
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whether a constitutive defect or a limited functional
reserve of the lymphatic system is a primary predis-
posing factor toward an overt clinical syndrome when
additional insults occur (i.e., comorbidity-driven
chronic inflammation or elevated CVP) or, vice versa,
a result of their long-term, potentially additive detri-
mental effects (35,36). The latter (i.e., a consequence
of comorbidities and of target organ damage with
diastolic dysfunction) would be in keeping with
morphological changes and impaired maximal
lymphatic pumping capacity reported in patients with
a Fontan circulation, in whom chronically increased
CVP would induce initial compensation of the after-
load but long-term failure (26). Conversely, an under-
lying predisposing defect would remind of cases with
secondary lymphedema, in which systemic alterations
in lymphatic drainage precede the clinical onset of
lymphedema and affect also the contralateral limbs
(37,38). Detection of lymphatic impairment also in the
upper limbs, in which not even trace edema was
detectable in either group compared with the calves or
ankles of some of our patients with HFpEF, suggests a
systemic nature of the phenomenon, although
involvement of other organ-specific microvascular
beds remains to be investigated.
Regardless of ‘which comes first’ considerations,
reduced capacity of the lymphatic system to prevent
or minimize development of edema could mark the
clinical and prognostic distinction between patients
with uncomplicated comorbidity and those present-
ing as HFpEF (3). Moreover, by targeting edema and
its dysfunctional and inflammatory implications,
improving lymphatic function could improve quality
of life, muscle performance, and exercise tolerance;
disrupt vicious inflammatory cycles; and reduce the
need or dose of diuretic treatment to maintain sus-
tained decongestion. Of note, although routinely
impractical in its surgical approach, successful
external thoracic duct drainage in advanced HF has
already shown therapeutic promise as a proof of
concept (39).
STUDY LIMITATIONS. In addition to the aforemen-
tioned lack of causality demonstration, which war-
rants additional dedicated studies, other limitations
deserve to be mentioned. Healthy subjects were cho-
sen as control subjects and comparison of HFpEF with
comorbidity-matched patients is missing; similarly, a
comparison between patients with HFpEF with and
without obesity (35) would further define the speci-
ficity of our findings. Of note, none of the drug classes
in use in the study, including calcium-channel
blockers (40), have been reported to adversely affect
lymphatic function in vivo. For our conclusions, weassumed similar osmotic pressures of albumin (sP),
critical for isovolumetric pressure ex vivo (32), be-
tween groups; as the accurate measurement of leaki-
ness of blood vessels to albumin (i.e., s) is
cumbersome and unfeasible in clinical settings, the
assumption was based on similar plasma albumin
concentrations. Notably, even if excess permeability
of blood vessels in HFpEF was demonstrated, the
relative compensation provided by lymphatics would
still remain inadequate. Finally, we assessed multiple
physiological parameters, and we cannot exclude the
presence of type I error; similarly, our sample size
prevented subphenotyping of the HFpEF cohort.
CONCLUSIONS
This study provides the first description of morpho-
logical and functional changes in the lymphatic
vasculature in HFpEF, resulting in reduced clearance
of extravasated fluid. Along with demonstration of a
reduced blood microvascular density in the skin, such
findings draw attention to a globally and systemically
defective microcirculation. This definition extends
beyond the traditional arterial dysfunction and
calls for better understanding of the role of arteries,
veins, lymphatics, and theirmutual crosstalk for tissue
fluid (and likely inflammatory) homeostasis in the
pathogenesis of this multifaceted, syndromic disease.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In
patients with HFpEF, systemic microvascular
dysfunction, including vascular rarefaction, involves both
capillary and lymphatic vessels, reducing lymphatic
reserve and dysregulating vascular–interstitial fluid
homeostasis.
TRANSLATIONAL OUTLOOK: Better understanding
of the structural and molecular mechanisms responsible
for reduced lymphatic reserve may facilitate the devel-
opment of pharmacological interventions that improve
interstitial fluid drainage in patients with HFpEF fluid
drainage.
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